Anser® VDZ

Simultaneously measures vedolizumab (VDZ) and antibodies to vedolizumab (ATV) levels in serum at any time during therapy.

For detailed information visit www.anservdz.com »

The Prometheus Anser® tests are quantitative monitoring assays that allow healthcare providers to measure and monitor both the levels of drug and anti-drug antibodies at anytime during therapy. Incorporating drug monitoring may clarify what factors are contributing to a patient’s loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action.

Sample insurance correspondence for PROMETHEUS® Anser® VZD

Anser® ADA

Simultaneously measures adalimumab (ADA) and antibodies to adalimumab (ATA) levels in serum at any time during therapy.

For detailed information visit www.anserada.com »

The Prometheus Anser® tests are quantitative monitoring assays that allow healthcare providers to measure and monitor both the levels of drug and anti-drug antibodies at anytime during therapy. Incorporating drug monitoring may clarify what factors are contributing to a patient’s loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action.

Sample insurance correspondence for PROMETHEUS® Anser® ADA

Anser® IFX

Simultaneously measures infliximab (IFX) and antibodies to infliximab (ATI) levels in serum at any time during therapy. Can also be used with IFX biosimilars.

For detailed information visit www.anserifx.com »


The Prometheus Anser® tests are quantitative monitoring assays that allow healthcare providers to measure and monitor both the levels of drug and anti-drug antibodies at anytime during therapy. Incorporating drug monitoring may clarify what factors are contributing to a patient’s loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action.

Sample insurance correspondence for PROMETHEUS® Anser® IFX